Catalent (CTLT) Stock Price, News & Analysis

$55.92
-0.11 (-0.20%)
(As of 04/24/2024 ET)
Today's Range
$55.79
$56.07
50-Day Range
$55.48
$58.77
52-Week Range
$31.45
$60.20
Volume
2.03 million shs
Average Volume
2.55 million shs
Market Capitalization
$10.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.46

Catalent MarketRank™ Stock Analysis

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
6.2% Downside
$52.46 Price Target
Short Interest
Healthy
4.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.10mentions of Catalent in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$21,749 Sold Last Quarter
Proj. Earnings Growth
325.00%
From $0.28 to $1.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.19 out of 5 stars

Medical Sector

322nd out of 907 stocks

Pharmaceutical Preparations Industry

147th out of 420 stocks

CTLT stock logo

About Catalent Stock (NYSE:CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CTLT Stock Price History

CTLT Stock News Headlines

Catalent (NYSE:CTLT) Coverage Initiated at StockNews.com
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Midday movers: Tesla, Coinbase rise; Uber falls
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
CTLT Apr 2024 17.500 call
CTLT Apr 2024 30.000 call
Catalent slashes 90 Bay Area jobs
In-Depth Examination Of 5 Analyst Recommendations For Catalent
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
4/25/2024
Next Earnings (Estimated)
6/10/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
17,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.46
High Stock Price Target
$63.50
Low Stock Price Target
$42.00
Potential Upside/Downside
-6.2%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
13 Analysts

Profitability

Net Income
$-256,000,000.00
Pretax Margin
-34.91%

Debt

Sales & Book Value

Annual Sales
$4.10 billion
Cash Flow
$3.24 per share
Book Value
$25.58 per share

Miscellaneous

Free Float
180,413,000
Market Cap
$10.12 billion
Optionable
Optionable
Beta
1.20
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

CTLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price target for 2024?

13 Wall Street analysts have issued 12-month price objectives for Catalent's shares. Their CTLT share price targets range from $42.00 to $63.50. On average, they anticipate the company's share price to reach $52.46 in the next year. This suggests that the stock has a possible downside of 6.2%.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2024?

Catalent's stock was trading at $44.93 at the beginning of the year. Since then, CTLT shares have increased by 24.5% and is now trading at $55.92.
View the best growth stocks for 2024 here
.

Are investors shorting Catalent?

Catalent saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 7,850,000 shares, an increase of 8.4% from the February 29th total of 7,240,000 shares. Based on an average trading volume of 2,700,000 shares, the days-to-cover ratio is currently 2.9 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024.
View our CTLT earnings forecast
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings data on Friday, February, 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.22. The company earned $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative trailing twelve-month return on equity of 2.43% and a negative net margin of 29.91%. Catalent's quarterly revenue was down 10.2% on a year-over-year basis. During the same period last year, the business posted $0.62 EPS.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.23%), Cambridge Investment Research Advisors Inc. (0.03%), Amalgamated Bank (0.03%), Mountain Pacific Investment Advisers Inc. ID (0.02%) and IFM Investors Pty Ltd (0.02%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano and Thomas W Hawkeswood.
View institutional ownership trends
.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CTLT) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners